More Videos:

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Cramer: Fed Up With the Parlor Games

Tickers in this article: NDLS ONXX
Editor's Note: This article was originally published at 6 a.m. EDT on Real Money on July 2. To see Jim Cramer's latest commentary as it's published, sign up for a free trial of Real Money.

NEW YORK (Real Money) -- Are you as tired as I am of the parlor game about what's driving this market? When I wake up these days, I look at China to get my usual dose of disappointment. Then I see how manipulated Japan is -- and in what direction it went -- and then I examine how horrible Europe is, and then I read stories about how the latest Fed guessing game is going. Only then do I look at how stocks are doing.

I am told to do all of this, in that order, by everyone I listen to. Some have told me -- people who are older and smarter than I am -- that, in order to figure out where the U.S. market will go, all I have to do is monitor Japan. Others say that China is pretty much in charge these days, and if China's banking system implodes, all bets are off. They say that, given the see-through nature of all those buildings in the major cities in China, that country is a ticking time bomb, especially if it needs to repatriate assets. Then others tell me that, if Spain and Italy turn and Europe gets going again, that means we'll be able to see a turn in China, which therefore means a turn here in the U.S.

But I keep thinking about Noodles and Onyx Pharma . That's right -- I keep thinking about what would have been if I'd begun looking at things from the perspective of who has the best new restaurant chain and who has the best growth in biotech. I keep thinking, in other words, that I would now be making a heck of a lot more money if I'd been U.S.-stock-centric.

Fortunately I had been able to see that Onyx could be a valuable piece of property. But that's only because I know Celgene and the challenge that Onyx presents to it in multiple myeloma treatment -- and also because my mother died of kidney cancer, which gave me a personal insight that drew me to Onyx's Nexavar franchise.